Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Mar;17(3):233–241. doi: 10.1111/j.1365-2125.1984.tb02337.x

Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

G P Hodsman, J R Zabludowski, C Zoccali, R Fraser, J J Morton, G D Murray, J I Robertson
PMCID: PMC1463367  PMID: 6324833

Abstract

The immediate and long-term effects of enalapril (MK421) and its lysine analogue (MK521) in once-daily dosage, were compared in a study of 12 normal subjects. Both compounds lowered blood pressure equally throughout 24 h without causing tachycardia. The biochemical changes with MK521 were more sustained than with MK421, but this did not affect the magnitude of blood pressure reduction. Twenty-four hours after the previous dose, with both active drugs, plasma renin concentration was significantly higher on day 8 than on day 1, though angiotensin I did not increase in proportion; this probably reflects a fall in renin-substrate with prolonged converting enzyme inhibition. There was an early natriuresis with each compound but this effect was no longer apparent after 8 days of continuous therapy. Both MK421 and MK521 were well tolerated with no serious side effects.

Full text

PDF
237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T., Kurz K., Cohen M. L. New inhibitor of angiotension-converting enzyme is stable on storage in plasma. N Engl J Med. 1981 Jun 18;304(25):1550–1550. doi: 10.1056/NEJM198106183042522. [DOI] [PubMed] [Google Scholar]
  2. Atkinson A. B., Brown J. J., Cumming A. M., Fraser R., Lever A. F., Leckie B. J., Morton J. J., Robertson J. I. Captopril in renovascular hypertension: long-term use in predicting surgical outcome. Br Med J (Clin Res Ed) 1982 Mar 6;284(6317):689–693. doi: 10.1136/bmj.284.6317.689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Atkinson A. B., Cumming A. M., Brown J. J., Fraser R., Leckie B., Lever A. F., Morton J. J., Robertson J. I. Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure. Br J Clin Pharmacol. 1982 Jun;13(6):855–858. doi: 10.1111/j.1365-2125.1982.tb01878.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Atkinson A. B., Morton J. J., Brown J. J., Davies D. L., Fraser R., Kelly P., Leckie B., Lever A. F., Robertson J. I. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition. Br Heart J. 1980 Sep;44(3):290–296. doi: 10.1136/hrt.44.3.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Atkinson A. B., Robertson J. I. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836–839. doi: 10.1016/s0140-6736(79)92186-x. [DOI] [PubMed] [Google Scholar]
  6. Biollaz J., Burnier M., Turini G. A., Brunner D. B., Porchet M., Gomez H. J., Jones K. H., Ferber F., Abrams W. B., Gavras H. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther. 1981 May;29(5):665–670. doi: 10.1038/clpt.1981.92. [DOI] [PubMed] [Google Scholar]
  7. Biollaz J., Schelling J. L., Jacot Des Combes B., Brunner D. B., Desponds G., Brunner H. R., Ulm E. H., Hichens M., Gomez H. J. Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol. 1982 Sep;14(3):363–368. doi: 10.1111/j.1365-2125.1982.tb01992.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brunner D. B., Desponds G., Biollaz J., Keller I., Ferber F., Gavras H., Brunner H. R., Schelling J. L. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol. 1981 May;11(5):461–467. doi: 10.1111/j.1365-2125.1981.tb01151.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burnier M., Biollaz J., Brunner H. R., Turini G. A., Gavras H. Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril. Am J Cardiol. 1982 Apr 21;49(6):1550–1551. doi: 10.1016/0002-9149(82)90386-1. [DOI] [PubMed] [Google Scholar]
  10. Dargie H. J., Ball S. G., Atkinson A. B., Robertson J. I. Converting enzyme inhibitors in hypertension and heart failure. Br Heart J. 1983 Apr;49(4):305–308. doi: 10.1136/hrt.49.4.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fraser R., Guest S., Young J. A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med. 1973 Sep;45(3):411–415. doi: 10.1042/cs0450411. [DOI] [PubMed] [Google Scholar]
  12. Garcia Del Rio C., Smellie W. S., Morton J. J. des-Asp-angiotensin I: its identification in rat blood and confirmation as a substrate for converting enzyme. Endocrinology. 1981 Feb;108(2):406–412. doi: 10.1210/endo-108-2-406. [DOI] [PubMed] [Google Scholar]
  13. Gavras H., Biollaz J., Waeber B., Brunner H. R., Gavras I., Davies R. O. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet. 1981 Sep 12;2(8246):543–547. doi: 10.1016/s0140-6736(81)90937-5. [DOI] [PubMed] [Google Scholar]
  14. Gross D. M., Sweet C. S., Ulm E. H., Backlund E. P., Morris A. A., Weitz D., Bohn D. L., Wenger H. C., Vassil T. C., Stone C. A. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther. 1981 Mar;216(3):552–557. [PubMed] [Google Scholar]
  15. Hodsman G. P., Brown J. J., Cumming A. M., Davies D. L., East B. W., Lever A. F., Morton J. J., Murray G. D., Robertson J. I. Enalapril (MK421) in the treatment of hypertension with renal artery stenosis. J Hypertens Suppl. 1983 Oct;1(1):109–117. [PubMed] [Google Scholar]
  16. Hodsman G. P., Brown J. J., Davies D. L., Fraser R., Lever A. F., Morton J. J., Murray G. D., Robertson J. I. Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis. Br Med J (Clin Res Ed) 1982 Dec 11;285(6356):1697–1699. doi: 10.1136/bmj.285.6356.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. MacGregor G. A., Markandu N. D., Bayliss J., Roulston J. E., Squires M., Morton J. J. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects. Br Med J (Clin Res Ed) 1981 Aug 8;283(6288):401–403. doi: 10.1136/bmj.283.6288.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. MacGregor G. A., Markandu N. D., Roulston J. E., Jones J. C., Morton J. J. The renin--angiotensin--aldosterone system in the maintenance of blood pressure, aldosterone secretion and sodium balance in normotensive subjects. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):95s–99s. doi: 10.1042/cs059095s. [DOI] [PubMed] [Google Scholar]
  19. Mancia G., Parati G., Pomidossi G., Grassi G., Bertinieri G., Buccino N., Ferrari A., Gregorini L., Rupoli L., Zanchetti A. Modification of arterial baroreflexes by captopril in essential hypertension. Am J Cardiol. 1982 Apr 21;49(6):1415–1419. doi: 10.1016/0002-9149(82)90353-8. [DOI] [PubMed] [Google Scholar]
  20. Millar J. A., Derkx F. H., McLean K., Reid J. L. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol. 1982 Sep;14(3):347–355. doi: 10.1111/j.1365-2125.1982.tb01990.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Patchett A. A., Harris E., Tristram E. W., Wyvratt M. J., Wu M. T., Taub D., Peterson E. R., Ikeler T. J., ten Broeke J., Payne L. G. A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280–283. doi: 10.1038/288280a0. [DOI] [PubMed] [Google Scholar]
  22. Rasmussen S., Damkjaer Nielsen M., Giese J. Captopril combined with thiazide lowers renin substrate concentration: implications for methodology in renin assays. Clin Sci (Lond) 1981 May;60(5):591–593. doi: 10.1042/cs0600591. [DOI] [PubMed] [Google Scholar]
  23. Semple P. F., Boyd A. S., Dawes P. M., Morton J. J. Angiotensin II and its heptapeptide (2-8), hexapeptide (3-8), and pentapeptide (4-8) metabolites in arterial and venous blood of man. Circ Res. 1976 Nov;39(5):671–678. doi: 10.1161/01.res.39.5.671. [DOI] [PubMed] [Google Scholar]
  24. Ulm E. H., Hichens M., Gomez H. J., Till A. E., Hand E., Vassil T. C., Biollaz J., Brunner H. R., Schelling J. L. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982 Sep;14(3):357–362. doi: 10.1111/j.1365-2125.1982.tb01991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Waite M. A. Measurement of concentrations of angiotensin I in human blood by radioimmunoassay. Clin Sci. 1973 Jul;45(1):51–64. doi: 10.1042/cs0450051. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES